R&D Focus: New report shows nearly 600 medicines in development for pediatric patients
By Andrew Powaleny | February 13, 2020
America’s biopharmaceutical researchers are committed to studying, developing and testing medicines to meet the unique needs of pediatric patients. New treatment options for infants, children and...
Read More
ICYMI: 2019 brings innovative medicines to patients
By Andrew Powaleny | January 17, 2020
New reports from the U.S. Food and Drug Administration (FDA) show a total of 55 novel new medicines were approved in 2019. Among these, 48 were approved by the Center for Drug Evaluation and...
Read More
ICYMI: Cancer death rate declines at record levels thanks to innovative medicines
By Andrew Powaleny | January 9, 2020
Each year, the American Cancer Society estimates the number of new cancer cases and deaths that will occur in the United States. For nearly 30 years, the trend towards fewer cancer deaths has been...
Read More
R&D Focus: Four ways the biopharmaceutical industry leads in delivering new treatments and cures
By Andrew Powaleny | December 9, 2019
In recent years, rapid advances in scientific discovery have ushered in a new era of medicine, transforming our ability to treat, and in some cases cure, some of the most challenging diseases,...
Read More
R&D Focus: It takes an ecosystem to deliver innovative new therapies
By Richard Moscicki, M.D. | November 14, 2019
We are living in a new era of medicine where innovations are transforming our ability to attack the cause of a disease, not just the symptoms. Today, concepts, such as cell and gene therapies, ...
Read More
Medicare Monday (100)
340B Spotlight (43)
Cost & Consequence (0)
